Gradipore Ltd. has entered into an agreement with Biomira Inc for the separation and purification of recombinant proteins based upon Gradipore's platform separations technology, Gradiflow. Under the terms of this agreement, Gradipore will provide a customized Gradiflow platform for transfer to Biomira. The agreement provides for the payment of certain performance-based fees to Gradipore.
Gradipore's core separations technology platform, Gradiflow, is a unique membrane-based process for large-scale biological separations and has a wide range of applications in research, scientific and commercial environments including blood purification and biological drug manufacturing. Unlike other large-scale blood purification technologies, Gradiflow can purify proteins and remove viral and bacterial pathogens simultaneously.
Under the agreement, Biomira will use Gradiflow to establish methods for isolating and purifying certain recombinant proteins. Gradipore scientists will establish a set of purification protocols internally that when developed will be transferred to Biomira for implementation and verification. For Biomira, this agreement provides access to the Gradiflow technology and a process for producing higher yields of recombinant proteins.
Dr. Hari Nair, CEO of Gradipore Inc said, "this agreement with Biomira is unique for Gradipore, because it is an investment in the future that, once successful, will open up opportunities for the widespread application of Gradiflow in the area of recombinant protein-based therapeutics. We are pleased to be associated with Biomira, a recognized and respected therapeutic company, on this groundbreaking application of Gradiflow."